Drug Approval | August 29, 2025
Moderna receives FDA approval for updated COVID-19 vaccines for LP.8.1 Variant of SARS-CoV-2
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
AINU is set to accelerate its expansion footprint, enhance operational capabilities
The submission is supported by results from the Phase 3b APEX study
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
